| Dr David Bryant, MD | |
|
817 N Emporia St, Wichita, KS 67214-3709 | |
| (316) 268-5927 | |
| (316) 291-7940 |
| Full Name | Dr David Bryant |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 29 Years |
| Location | 817 N Emporia St, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124000435 | NPI | - | NPPES |
| 200550700A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 04-33095 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| William Newton Hospital | Winfield, KS | Hospital |
| Wesley Medical Center | Wichita, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Via Christi Hospitals Wichita Inc | 5799696944 | 70 |
News Archive
Researchers at Swansea University have received £230,000 to develop the world's first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body's associated response.
A new study using brevetoxin-2, a compound produced naturally by marine algae, stimulated nerve cell growth and plasticity in cultured mouse neurons. This research advances a potentially new pharmacological treatment to aid recovery of brain function following a stroke or other traumatic brain injury.
Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.
Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.
› Verified 1 days ago
| Entity Name | Ascension Via Christi Hospitals Wichita Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871589333 PECOS PAC ID: 5799696944 Enrollment ID: O20031118000404 |
News Archive
Researchers at Swansea University have received £230,000 to develop the world's first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body's associated response.
A new study using brevetoxin-2, a compound produced naturally by marine algae, stimulated nerve cell growth and plasticity in cultured mouse neurons. This research advances a potentially new pharmacological treatment to aid recovery of brain function following a stroke or other traumatic brain injury.
Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.
Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.
› Verified 1 days ago
| Entity Name | Cancer Center Of Kansas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841251394 PECOS PAC ID: 5395732820 Enrollment ID: O20040427001505 |
News Archive
Researchers at Swansea University have received £230,000 to develop the world's first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body's associated response.
A new study using brevetoxin-2, a compound produced naturally by marine algae, stimulated nerve cell growth and plasticity in cultured mouse neurons. This research advances a potentially new pharmacological treatment to aid recovery of brain function following a stroke or other traumatic brain injury.
Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.
Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Bryant, MD Po Box 1897, Wichita, KS 67201-1897 Ph: (316) 268-8131 | Dr David Bryant, MD 817 N Emporia St, Wichita, KS 67214-3709 Ph: (316) 268-5927 |
News Archive
Researchers at Swansea University have received £230,000 to develop the world's first smart vaccine device that will both deliver the COVID-19 vaccine and measure its efficacy through monitoring the body's associated response.
A new study using brevetoxin-2, a compound produced naturally by marine algae, stimulated nerve cell growth and plasticity in cultured mouse neurons. This research advances a potentially new pharmacological treatment to aid recovery of brain function following a stroke or other traumatic brain injury.
Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.
Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.
› Verified 1 days ago
Karl Hamouche, Radiology Medicare: Medicare Enrolled Practice Location: 551 N Hillside St Ste 320, Wichita, KS 67214 Phone: 316-685-1367 | |
Dr. Larry C Graham Ii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3600 E Harry St, Wichita, KS 67218 Phone: 316-689-5050 Fax: 316-689-6192 | |
Tim Edward Stone, Radiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2665 | |
Dr. Donald C S Tan, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 817 N Emporia St, Via Christi Cancer Center, Wichita, KS 67214 Phone: 316-268-5927 | |
Elizabeth Perez-elmore, RN BSN Radiology Medicare: Not Enrolled in Medicare Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-685-2221 | |
Mike Lam, DO Radiology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-293-2635 | |
Dr. Timothy C Benning, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3600 E Harry St, Wichita, KS 67218 Phone: 316-689-6173 |